Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 7, 2004, Pages 905-909

  Marra, Fawziah ^a,b   Cox, V C ^b   FitzGerald, J M ^c   Moadebi, S ^a   Elwood, R K ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Adverse events; Allergic hepatitis; Liver transplant; Multidrug resistance; Tuberculosis

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; INDIA; LIVER NECROSIS; LIVER TRANSPLANTATION; LUNG TUBERCULOSIS; LYMPHADENITIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RASH;

ADULT; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; CIPROFLOXACIN; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; LIVER; LIVER DISEASES; LIVER TRANSPLANTATION; NECROSIS; PYRAZINAMIDE; TUBERCULOSIS, PULMONARY;

EID: 3242736548     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
2. Goble M, Horsburgh C R Jr, Waite D, et al. Treatment of isoniazid and rifampin-resistant tuberculosis. Am Rev Respir Dis 1988; 137 (Suppl): 24.
3. Iseman M D, Madsden L A. Drug-resistant tuberculosis. Clin Chest Med 1989; 10: 341-353.
4. Khan K, Muennig P, Behta M, Zivin J G. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347: 1850-1859.
5. Weltman A C, DeFernando G T, Washko R, Lipsky W M. Death associated with therapy for nosocomially acquired multiple drug resistant tuberculosis. Chest 1996; 110: 279-281.
6. Liu Z X, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 467-486.
7. Goodman Z D. Drug hepatotoxicity. Clin Liver Dis 2002; 6: 381-397.
8. Podevin P, Biour M. Drug-induced 'allergic hepatitis'. Clin Rev Allergy Immunol 1995; 13: 223-244.
9. Grassmick B K, Lehr V, Sundareson A S. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother 1992; 26: 636-639.
10. Contreras M Á, Luna R, Mulero J, Andreu J L. Severe ciprofloxacin-induced acute hepatitis. Eur J Clin Microbiol Infect Dis 2001; 20: 434-435.
11. Zaidi S A. Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin. Am J Med Sci 2003; 325: 31-33.
12. Corbella X, Vadillo M, Cabellos C. Hypersensitivity hepatitis due to pyrazinamide. Scand J Infect Dis 1995; 27: 93-94.
13. Lees A W, Allan G W, Smith J, Tyrrell W F, Fallon R J. Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971; 52: 182-190.
14. Dutau H, Saadjian M, Bonneau V, Charpin D. Unsuccessful rapid desensitization to rifampicin. Allergy 2000; 55: 778-789.
15. Assem E S K, Ndoping N, Nicholson H, Wade J R. Liver damage and isoniazid allergy. Clin Exp Allergy 1969; 5: 439-442.
16. Rudoy R, Stuemky J, Poley J R. Isoniazid administration and liver injury. Am J Dis Child 1973; 125; 733-736.
17. Girling D J. Adverse effects of antituberculosis drugs. Drugs 1982; 23: 56-74.
18. Maddrey W C. Drug-related acute and chronic hepatitis. Clin Gastroenterol 1980; 9: 213-224.
19. Horn D L, Hewlett D, Alfalla C, Peterson S, Opal S M. Limited tolerance of of loxacin and pyrazinamide prophylaxis against tuberculosis [letter]. N Engl J Med 1994; 330: 1241.
20. Papastavros T, Dolovich L R, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of multidrug-resistant tuberculosis. CMAJ 2002; 167: 131-136.
21. Lou H-X, Shallo M A, McKaveney T P. Limited tolerability of levofloxacin and pyrazinamide for multidrug resistant tuberculosis prophylaxis in solid organ transplant population. Pharmacother 2002; 22: 701-704.
22. Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations, 2001. MMWR 2001: 50: 733-735.
23. Meyers B R, Halpern M, Sheiner P, Mendelson M H, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994; 58: 301-306.
24. Stoblen F, Neuhaus R, Neumann K, et al. Tuberculosis in liver transplant recipients: recurrence after transplantation? Transplant Proc 1994; 26: 3604-3605.
25. Aguado J M, Herrero J A, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63: 1278-1286.